Patient-reported preferences for IL-17 and IL-23 inhibitor dosing frequencies in psoriasis management

Summary: Abstract Body: Biologic dosing frequency is a key concern among psoriasis (PsO) patients and physicians, yet dosing optimization remains a challenge. This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every 12 weeks, guselkumab (GUS) every 8 weeks, and ixekizumab (IXE) every 4 weeks, in managing PsO. This phone survey study evaluated 87 adults on RZB (n=29), GUS (n=35), or IXE (n=23) from 2019 onward at two clinical sites. Patients were assessed for: 1) baseline PsO bothersome severity (0- never bothered to 2-very bothered); 2) current dosing frequency satisfaction (0- very unsatisfied to 4-very satisfied); 3) frequency of PsO flares (0- never to 3- all the time); and 4) preferred doing frequency (0- less, 1- no change, 2- more). Most patients were males (57.5%) with an average age of 54.1 years and an average treatment duration of 19.0 months. At baseline before treatment, 87% were ‘very bothered’ by their PsO. After treatment, 86% were either ‘3-somewhat’ or ‘4-very satisfied’ with their current dosing schedule, with no significant differences between each drug (p=0.7). Although 39% of IXE users desired less frequent dosing compared to 21% of RZB and 26% of GUS patients, differences in satisfaction were not statistically significant, likely due to the limited sample size (OR 2.36; 95% CI 0.70–8.45; p = 0.2). The higher proportion of IXE patients seeking “less frequent dosing” suggests that injection frequency influences patient comfort and treatment burden. Previous studies report that generally, patients prefer lower frequency dosing schedules which improves adherence and quality of life. While this preliminary study supports those conclusions, further research is required to elucidate the impact of dosing frequency on long term outcomes. Omar Alani¹, S. Minhaj Rahman², Carrington Webb³, Fahad Ahmed⁴, Nicole Seminara³, Adel Haque⁵ 1. Icahn School of Medicine at Mount Sinai, New York, NY, United States. 2. University of Rochester School of Medicine and Dentistry, Rochester, NY, United States. 3. Piedmont Plastic Surgery & Dermatology, Charlotte, NC, United States. 4. University of Miami Health System, Miami, FL, United States. 5. Dermatology Partners, Macungie, PA, United States. Clinical Research: Epidemiology and Observational Research